CD14 and cancer: Moreover, Krieg et al. proposed that abundant circulating CD14+ CD16− HLA-DRhi cells before anti-PD-1 therapy facilitate the infiltration of circulating T lymphocytes into the tumor, enhancing the cytotoxicity against cancer cells [32].